We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Epigenetic Similarity in Cancer Cells Characterizes More Aggressive Tumors

By LabMedica International staff writers
Posted on 29 Aug 2016
Print article
Image: A microscopic view of a colon cancer section (Photo courtesy of IDIBELL-Bellvitge Biomedical Research Institute).
Image: A microscopic view of a colon cancer section (Photo courtesy of IDIBELL-Bellvitge Biomedical Research Institute).
Cancer researchers have found that the degree of epigenetic similarity among colorectal tumor cells was reflected in patients as significantly shortened relapse-free survival time and shortened time of overall survival.

Few biomarkers for predicting outcomes of patients with colorectal cancer have been validated. This is in part due to the genetic and molecular heterogeneity of colorectal tumors not only among different patients, but also within the tumors themselves.

To better understand the puzzle of tumor cell heterogeneity, investigators at IDIBELL-Bellvitge Biomedical Research Institute (Barcelona, Spain) analyzed DNA methylation profiles of the digestive tract surface and the central bulk and invasive front regions of 79 colorectal tumors and 23 associated liver metastases, obtained from two hospitals in Spain. They also analyzed samples for KRAS and BRAF mutations, 499,170 single nucleotide polymorphisms, and performed immunohistochemical analyses.

Results showed that among three defined tumor sections, differences in DNA methylation were most pronounced at the site of the tumor-host interface. Tumor samples collected from areas closer to the gastrointestinal transit most frequently shared methylation events with metastases. When individual coefficients were calculated to quantify heterogeneity, epigenetic homogeneity was found to be significantly associated with short time of relapse-free survival and short time of overall survival.

"In patients with colorectal cancer, we determined the epigenome of three regions of each individual tumor. The area looking at the beginning of the digestive tract, central and growing into the blood vessels results demonstrate the existence of intratumoral heterogeneity, which means that each region has differences," said senior author Dr. Manel Esteller, director of the epigenetics and cancer biology program at Bellvitge Biomedical Research Institute. "The more epigenetically different region is the invasive front, the area that interacts with adjacent normal tissues. We have also seen that the intratumoral region most similar to metastatic stages is the oldest of the tumor, which suggests spreading even in apparently early stages. Furthermore, data show that the more similar the three regions are, the more aggressive the tumor is, just as if the cell population with more proliferation capacity had already been selected. Measurements of the level of molecular heterogeneity of tumors could then be used as predictors of their prognosis and potential to acquire resistance to therapies."

The study was published in the August 10, 2016, online edition of the journal Gastroenterology.

Related Links:
IDIBELL-Bellvitge Biomedical Research Institute

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.